about
Tamoxifen or letrozole versus standard methods for women with estrogen-receptor positive breast cancer undergoing oocyte or embryo cryopreservation in assisted reproductionTamoxifen or letrozole versus standard methods for women with estrogen-receptor positive breast cancer undergoing oocyte or embryo cryopreservation in assisted reproductionBreast cancer in the personal genomics eraTamoxifen: catalyst for the change to targeted therapyTamoxifen (ICI46,474) as a targeted therapy to treat and prevent breast cancerQ24798021Mechanisms of oestrogen receptor (ER) gene regulation in breast cancerThe discovery and development of selective estrogen receptor modulators (SERMs) for clinical practiceCurrent treatment of early breast cancer: adjuvant and neoadjuvant therapyProtective effects of white button mushroom (Agaricus bisporus) against hepatic steatosis in ovariectomized mice as a model of postmenopausal womenA Drug-Centric View of Drug Development: How Drugs Spread from Disease to DiseaseTransactivation Function-2 of Estrogen Receptor α Contains Transactivation Function-1-regulating ElementSynthesis and antiproliferative activity of hydroxyferrocifen hybrids against triple-negative breast cancer cells.Phenotype anchoring in zebrafish reveals a potential role for matrix metalloproteinases (MMPs) in tamoxifen's effects on skin epithelium.Strategies for power calculations in predictive biomarker studies in survival dataEffects of tamoxifen on vaginal blood flow and epithelial morphology in the ratTamoxifen-poly(ethylene glycol)-thiol gold nanoparticle conjugates: enhanced potency and selective delivery for breast cancer treatmentTamoxifen as the first targeted long-term adjuvant therapy for breast cancerStapled BIG3 helical peptide ERAP potentiates anti-tumour activity for breast cancer therapeutics.New hypotheses and opportunities in endocrine therapy: amplification of oestrogen-induced apoptosis.PharmGKB summary: tamoxifen pathway, pharmacokineticsNicastrin and Notch4 drive endocrine therapy resistance and epithelial to mesenchymal transition in MCF7 breast cancer cells.Brefeldin A-inhibited guanine nucleotide-exchange protein 3 (BIG3) is predicted to interact with its partner through an ARM-type α-helical structureOptimizing mouse models for precision cancer prevention.Parallel synthesis of a desketoraloxifene analogue library via iodocyclization/palladium-catalyzed coupling.Molecular mechanisms of tamoxifen therapy for cholangiocarcinoma: role of calmodulin.Identification and pharmacological characterization of cholesterol-5,6-epoxide hydrolase as a target for tamoxifen and AEBS ligands.Selective estrogen receptor modulators: tissue specificity and clinical utility.Nuclear receptor modulation--role of coregulators in selective estrogen receptor modulator (SERM) actions.The evolution of nonsteroidal antiestrogens to become selective estrogen receptor modulatorsAcquired resistance to selective estrogen receptor modulators (SERMs) in clinical practice (tamoxifen & raloxifene) by selection pressure in breast cancer cell populationsA new approach to desketoraloxifene analogs from oxygen-bearing 3-iodobenzo[b]thiophenes prepared via iodocyclizationScientific rationale for postmenopause delay in the use of conjugated equine estrogens among postmenopausal women that causes reduction in breast cancer incidence and mortality.FOXA1 is a key determinant of estrogen receptor function and endocrine responseInduced protein degradation: an emerging drug discovery paradigm.Xanthohumol suppresses oestrogen-signalling in breast cancer through the inhibition of BIG3-PHB2 interactions.Molecular mechanisms of oestrogen and SERMs in endometrial carcinogenesis.In-vitro Antiproliferative Activity of New Tetrahydroisoquinolines (THIQs) on Ishikawa Cells and their 3D Pharmacophore Models.Synthesis and Pharmacological Evolution of Tetrahydroisoquinolines as Anti Breast Cancer Agents.Pharmacological relevance of endoxifen in a laboratory simulation of breast cancer in postmenopausal patients.
P2860
Q24197765-C014FA0F-1556-4B36-AE7B-AB70D1265F19Q24202513-41D18217-C50E-43AA-B8D5-BC122F71BA70Q24602679-F41479A5-4F20-42EC-9372-47583CA2931FQ24652988-3C607CBE-BE21-45AF-900C-F7DE9F853FE2Q24670339-6A4E1832-C2AC-472C-84BF-AC09542421D7Q24798021-9150D286-6DAB-4EF6-BD70-4F7D276B339FQ26765380-F43B870E-0E4D-4343-8D18-612226C27ED9Q26830744-986E3444-062C-4449-91BF-2B095CFDC222Q27011658-A0B2656C-2C1B-46BD-A099-9FC3E4ED91ADQ28477621-DBE8942C-B09B-470F-8828-595DB65AA77DQ28551652-682AE154-64CE-4BEB-8146-4847968F95BBQ30375133-B9270A97-F1CC-4B0B-9C26-7200F6180EB7Q30683354-041A3959-F90C-47DC-B868-8D2B3EFD15CAQ30727473-940D9E91-52A3-4B9D-94AE-AF3E719611F4Q31132692-F35E2C0B-9A1F-4712-BD57-602B98DFF3F0Q33257471-4ED05C1A-97D1-468A-AED2-1772D6C45023Q33516083-6CC74336-C9C5-45A4-8BEB-8B4604C3C549Q33642104-CE76E473-CD90-437A-B3F4-ABF575D99496Q33687329-EB452358-7164-4036-868E-FD798A08DBB1Q33841512-A852009F-0DA0-4EDD-9595-A3D294C50463Q33855494-72F5063A-B2E8-4E96-8E91-2D7197C17060Q33892801-F5DC7D04-92C9-41F5-A2E4-1D4334D7EC91Q33896624-B7C7043C-DFA3-49D9-AE2C-8DE6B922E46CQ33919192-0202EC24-D5B3-4311-B351-98ED65F6032BQ33948346-74D1B1A5-2A22-4527-97A6-477460417DB2Q34000409-F1D3F1EC-F1C1-4B80-8A21-BE13345424C3Q34068091-1B7493C8-95EB-40B3-AD42-946A0ADA3EFCQ34134828-6F1560E4-BC39-4B92-8634-4E3968B397B9Q34315391-B687EDE4-0617-4E72-8E05-C63E31A64273Q34315816-FCDF225D-C4B8-4A2A-BCF3-8B60AE3BF571Q34315889-FFE1D9BE-4C59-42A7-97DB-B99E31D174C2Q34339919-F22E3C7D-2911-4233-8ACD-0D679C07F1B5Q34362281-E3412463-24FA-42B7-9722-765241668AD2Q34508204-17B92112-1122-41E4-9D56-5F4523E64E51Q34545841-7EA4B0DB-D144-4BCA-8CF6-201BC68EBEB5Q34648456-2A451D3D-2244-41FB-B396-0047A27719EFQ34652138-2A6EAB64-5E80-4B4D-AEE7-75D1C56501FEQ34688033-C3DD405D-4FF4-43B6-B97D-50B34D76E386Q34707783-8B0C32D1-F96F-4608-B9D1-BA13ED0E1307Q34736986-810B7952-F721-4F3F-9B2F-06FA9F4CB2F4
P2860
description
2003 nî lūn-bûn
@nan
2003 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի մարտին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Tamoxifen: a most unlikely pioneering medicine.
@ast
Tamoxifen: a most unlikely pioneering medicine.
@en
Tamoxifen: a most unlikely pioneering medicine.
@nl
type
label
Tamoxifen: a most unlikely pioneering medicine.
@ast
Tamoxifen: a most unlikely pioneering medicine.
@en
Tamoxifen: a most unlikely pioneering medicine.
@nl
prefLabel
Tamoxifen: a most unlikely pioneering medicine.
@ast
Tamoxifen: a most unlikely pioneering medicine.
@en
Tamoxifen: a most unlikely pioneering medicine.
@nl
P2860
P356
P1476
Tamoxifen: a most unlikely pioneering medicine.
@en
P2093
V Craig Jordan
P2860
P2888
P304
P356
10.1038/NRD1031
P577
2003-03-01T00:00:00Z